These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 32467066)

  • 21. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria.
    Zubiaga-Fernandez L; Testera-Montes A; Rondon C; Perez-Sanchez N; Gomez-Perez F; Vega-Chicote JM; Bartra J; Ferrer M; Eguiluz-Gracia I; Torres MJ
    Clin Exp Allergy; 2024 Jun; 54(6):402-411. PubMed ID: 38343206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
    Jain V; Giménez-Arnau A; Hayama K; Reich A; Carr W; Tillinghast J; Dahale S; Lheritier K; Walsh P; Zharkov A; Hugot S; Haemmerle S
    J Allergy Clin Immunol; 2024 Feb; 153(2):479-486.e4. PubMed ID: 37866460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria.
    Can PK; Etikan P; Degirmentepe EN; Kocaturk E
    Asian Pac J Allergy Immunol; 2024 Jun; 42(2):132-137. PubMed ID: 33638627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Hydroxychloroquine and Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study.
    Khan N; Epstein TG; DuBuske I; Strobel M; Bernstein DI
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3300-3305. PubMed ID: 36115542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remission of chronic urticaria in patients treated with omalizumab.
    Cvenkel K; Bizjak M; Šelb J; Košnik M
    Acta Dermatovenerol Alp Pannonica Adriat; 2024 Jun; 33(2):59-61. PubMed ID: 38741391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
    Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
    J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?
    Asero R
    Eur Ann Allergy Clin Immunol; 2020 Nov; 52(6):268-270. PubMed ID: 32191021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
    Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
    Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria.
    Sirufo MM; Bassino EM; De Pietro F; Ginaldi L; De Martinis M
    Int J Immunopathol Pharmacol; 2021; 35():20587384211065870. PubMed ID: 35170369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers.
    Türk M; Carneiro-Leão L; Kolkhir P; Bonnekoh H; Buttgereit T; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):113-124. PubMed ID: 31374358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-life, long-term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria.
    Apalla Z; Sidiropoulos T; Kampouropoulou E; Papageorgiou M; Lallas A; Lazaridou E; Smaragdi M; Delli F
    Eur J Dermatol; 2020 Dec; 30(6):716-722. PubMed ID: 33258453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: Clinical features, associated conditions and indicators of treatment response.
    Özçeker D; Can PK; Terzi Ö; Ornek SA; Değirmentepe EN; Kızıltac K; Sarac E; Kocatürk E
    Pediatr Allergy Immunol; 2023 Feb; 34(2):e13925. PubMed ID: 36825740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
    Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
    Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
    Salman A; Demir G; Bekiroglu N
    Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature.
    Kasperska-Zajac A; Jarząb J; Żerdzińska A; Bąk K; Grzanka A
    Int J Immunopathol Pharmacol; 2016 Jun; 29(2):320-8. PubMed ID: 26729404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Maurer M; Ensina LF; Gimenez-Arnau AM; Sussman G; Hide M; Saini S; Grattan C; Fomina D; Rigopoulos D; Berard F; Canonica GW; Rockmann H; Irani C; Szepietowski JC; Leflein J; Bernstein JA; Peter JG; Kulthanan K; Godse K; Ardusso L; Ukhanova O; Staubach P; Sinclair R; Gogate S; Thomsen SF; Tanus T; Ye YM; Burciu A; Barve A; Modi D; Scosyrev E; Hua E; Letzelter K; Varanasi V; Patekar M; Severin T;
    Lancet; 2024 Jan; 403(10422):147-159. PubMed ID: 38008109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria.
    Salman A; Comert E
    J Cutan Med Surg; 2019; 23(5):496-500. PubMed ID: 31030540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study.
    Hide M; Igarashi A; Yagami A; Chinuki Y; Inomata N; Fukunaga A; Kaiser G; Wang J; Matsushima S; Greenberg S; Khalil S
    Allergol Int; 2018 Apr; 67(2):243-252. PubMed ID: 29102514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.